Achieve Life Sciences, Inc. (ACHV) News

Achieve Life Sciences, Inc. (ACHV): $5.64

0.64 (+12.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACHV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter ACHV News Items

ACHV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACHV News Highlights

  • ACHV's 30 day story count now stands at 5.
  • Over the past 27 days, the trend for ACHV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ACHV are III and NC.

Latest ACHV News From Around the Web

Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022

SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its fourth quarter and year-end 2021 financial results and provide an update on the cytisinicline development program on Thursday, March 10, 2022, at 4:30 PM EST. To access the webcast, log

Yahoo | February 24, 2022

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Since Our Last Update Since our last update , Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced several milestones. In January, Achieve’s pivotal, Phase III ORCA-2 1 trial had its last subject, last follow up, and the confirmatory Phase III ORCA-3 trial was initiated. In addition, Achieve hosted a key opinion leader panel

Yahoo | February 4, 2022

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award

SEATTLE and VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations. Achieve’s Board of Directors approved the new employment inducement grant of stock options

Yahoo | February 3, 2022

Achieve Life Sciences Announces Participation in February Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during February 2022. Winter Wonderland Best Ideas Virtual Investor Conference Date: T

Yahoo | February 2, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time.

Yahoo | January 28, 2022

Achieve Life commences Phase 3 trial of cytisinicline for smoking cessation

Achieve Life Sciences (ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate

Seeking Alpha | January 25, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in the United States. ORCA-3 will evaluate the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites. Similar to the first registrational Phase 3 ORCA-2 trial, ORCA-3 participants will be randomized to one of three study arms to evaluate cytisinicline administered for either 6 or 12 weeks, compared to plac...

Benzinga | January 25, 2022

Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers. ORCA-3 participants will be randomized to one of three study arms to evaluate cytisinicline administered for either 6 or 12 weeks, compared to placebo. Related: Achieve Life Sciences Secures M Loan Facility To Fund Smoking Cess

Yahoo | January 25, 2022

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: H.C. Wainwright BIOCONNECT Virtual Conference: Date: January 10, 2022 Time: 7:00 am ET Investors can register for the conference HERE . Following the conference, a webcast replay of the presentation will be available on Full story available on Benzinga.com

Benzinga | January 6, 2022

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Topline ORCA-2 Results Expected in Q2 2022SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021. The ORCA-2 trial is the first

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4056 seconds.